Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00061945 · OUTCOME

Minimal Residual Disease (MRD) During Treatment With Alemtuzumab (Phase II)

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia · Source last updated 2022-05-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
9 years 4 months

What was measured

Minimal Residual Disease measures the presence of of circulating leukemia cells in the body. Patients that report a Complete Response (CR) during treatment are further tested to determine the presence of small amounts of circulating leukemia cells. Here we report the number of patients who were MRD negative.

Analysis population: Patients who reported a Complete Response (CR) during treatment and were analyzed for the presence of circulating leukemia cells.

Groups in this outcome

Phase II - Alemtuzumab and Combination Chemotherapy

See detailed description or participant flow.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase II - Alemtuzumab and Combination Chemotherapy51

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Phase II - Alemtuzumab and Combination Chemotherapy16Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        16
denoms
  1. counts
    1. group Id
      OG000
      value
      51
    units
    Participants
description
Minimal Residual Disease measures the presence of of circulating leukemia cells in the body. Patients that report a Complete Response (CR) during treatment are further tested to determine the presence of small amounts of circulating leukemia cells. Here we report the number of patients who were MRD negative.
groups
  1. description
    See detailed description or participant flow.
    id
    OG000
    title
    Phase II - Alemtuzumab and Combination Chemotherapy
param Type
COUNT_OF_PARTICIPANTS
population Description
Patients who reported a Complete Response (CR) during treatment and were analyzed for the presence of circulating leukemia cells.
reporting Status
POSTED
time Frame
9 years 4 months
title
Minimal Residual Disease (MRD) During Treatment With Alemtuzumab (Phase II)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice